Pain Reduction With Oral Methotrexate in Knee Osteoarthritis

Уменьшение боли при остеоартрите коленного сустава при пероральном применении метотрексата
Philip G. Conaghan, David John Torgerson, Ada Keding, Catherine Elizabeth Hewitt, Christopher John Edwards, Nigel Arden, Fiona E. Watt, Robert J. Moots, Terence W O’Neill, Toby Garrood, Fraser N Birrell, Michael Doherty, M.A. Bowes, David Lloyd Scott, Edward Roddy, Sarah R. Kingsbury, Puvan Tharmanathan, Catherine Arundel, Michelle Watson, Sarah Jane Ronaldson, Michael Green, Gulam Patel, Phil J. Walmsley, Tom P Sheeran
2024-07-29

knee osteoarthritisknee painnumerical rating scaleoral methotrexaterandomized placebo-controlled trial
BACKGROUND: Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. OBJECTIVE: To assess symptomatic benefits of methotrexate in knee OA (KOA). DESIGN: A multicenter, randomized, double-blind, placebo-controlled trial done between 13 June 2014 and 13 October 2017. (ISRCTN77854383; EudraCT: 2013-001689-41). SETTING: 15 secondary care musculoskeletal clinics in the United Kingdom. PARTICIPANTS: A total of 207 participants with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months with inadequate response to current medication were approached for inclusion. INTERVENTION: Participants were randomly assigned 1:1 to oral methotrexate once weekly (6-week escalation 10 to 25 mg) or matched placebo over 12 months and continued usual analgesia. MEASUREMENTS: The primary end point was average knee pain (numerical rating scale [NRS] 0 to 10) at 6 months, with 12-month follow-up to assess longer-term response. Secondary end points included knee stiffness and function outcomes and adverse events (AEs). RESULTS: = 0.008). Treatment adherence analysis supported a dose-response effect. Four unrelated serious AEs were reported (methotrexate: 2, placebo: 2). LIMITATION: Not permitting oral methotrexate to be changed to subcutaneous delivery for intolerance. CONCLUSION: Oral methotrexate added to usual medications demonstrated statistically significant reduction in KOA pain, stiffness, and function at 6 months. PRIMARY FUNDING SOURCE: Versus Arthritis.
1
A multicenter randomized, double-blind, placebo-controlled trial evaluated weekly oral methotrexate for symptomatic knee osteoarthritis over 12 months.
2
Four unrelated serious adverse events occurred, with two in the methotrexate group and two in the placebo group.
3
Oral methotrexate added to usual analgesia produced statistically significant improvements in knee pain, stiffness, and function at 6 months.
4
The trial did not permit switching to subcutaneous methotrexate for intolerance, limiting management of oral-treatment intolerance.
5
Treatment-adherence analysis supported a dose-response relationship for methotrexate’s symptomatic benefits.

symptomatic, radiographic knee osteoarthritis with persistent knee pain

the effects of oral methotrexate on knee osteoarthritis pain, stiffness, and function

Publication Details
Publication Date
2024-07-29
Journal
Publisher
ISSN
Cited by
47
Access Type
Author Information
Authors
Philip G. Conaghan
David John Torgerson
Ada Keding
Catherine Elizabeth Hewitt
Christopher John Edwards
Nigel Arden
Fiona E. Watt
Robert J. Moots
Terence W O’Neill
Toby Garrood
Fraser N Birrell
Michael Doherty
M.A. Bowes
David Lloyd Scott
Edward Roddy
Sarah R. Kingsbury
Puvan Tharmanathan
Catherine Arundel
Michelle Watson
Sarah Jane Ronaldson
Michael Green
Gulam Patel
Phil J. Walmsley
Tom P Sheeran
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%